Identification of selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascadeAmanda J. Watson(University of Manchester), Donald Ogilvie(Bioscience Research)F1000ResearchAugust 23, 201610.12688/f1000research.8724.2Cited by 6SaveCiteExport RISWatch citationsRelated PapersAZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer|Cancer Research|2005|710Identification of selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascade|F1000Research|2016|6